Greenwich LifeSciences (NASDAQ:GLSI) Shares Down 4%

Greenwich LifeSciences, Inc. (NASDAQ:GLSI)’s stock price fell 4% during trading on Wednesday . The company traded as low as $12.36 and last traded at $12.62. 28,642 shares traded hands during mid-day trading, a decline of 37% from the average session volume of 45,720 shares. The stock had previously closed at $13.14.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of Greenwich LifeSciences in a research report on Wednesday, February 28th.

Greenwich LifeSciences Price Performance

The business has a 50-day simple moving average of $15.49 and a 200-day simple moving average of $11.81. The firm has a market capitalization of $162.55 million, a PE ratio of -18.03 and a beta of 1.38.

Greenwich LifeSciences (NASDAQ:GLSI) last issued its quarterly earnings data on Monday, April 15th. The company reported ($0.21) earnings per share (EPS) for the quarter. On average, research analysts expect that Greenwich LifeSciences, Inc. will post -0.76 earnings per share for the current year.

Insider Buying and Selling at Greenwich LifeSciences

In other Greenwich LifeSciences news, CEO Snehal Patel bought 1,500 shares of the business’s stock in a transaction dated Wednesday, March 20th. The shares were purchased at an average price of $17.68 per share, with a total value of $26,520.00. Following the completion of the purchase, the chief executive officer now owns 5,345,277 shares in the company, valued at approximately $94,504,497.36. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have purchased a total of 23,800 shares of company stock worth $327,722 over the last ninety days. Company insiders own 52.86% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.